Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by SkywalkerofLukeon May 10, 2023 3:27pm

142 Views

Post# 35441494

CEO Interview

Here’s an interview with the AGN.c AGNPF CEO on their recent news that they received a notice of Allowance from the US Patent and Trademark Office for patent application for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast).

More than 1 in 7, that is 15% of US adults or 37 million people, are estimated to have chronic kidney disease and as many as 9 in 10 adults do not know they have it. AGN is focused on discovering new therapeutic uses for drugs that are off patent and have a well-known safety history, but have never been marketed in the U.S. or Europe like Repirinast.

If AGN can secure this patent the addressable market is huge.

https://www.youtube.com/watch?v=Ot-kWEvA3m0

<< Previous

Bullboard Posts

Next >>

Get a better understanding of the psychology of options trading